News summary

MetaVia’s DA-1726 shows liver, weight benefits in preclinical study

Source: Longevity Technology • Published: 17 Nov 2026, 11:31

Summarized by Masters of Longevity from Longevity Technology.

1726 reduced body weight and improved liver measures versus retatrutide.

MetaVia’s DA-1726 shows liver, weight benefits in preclinical study
Key Takeaways
  • MetaVia presented preclinical head-to-head data at ObesityWeek 2026.
  • DA-1726 reduced body weight in the reported rodent models.
  • DA-1726 showed liver-related benefits versus retatrutide in rodents.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.